Drug development that cares

Tuning the injectability and release properties of microparticles starts with controlling their exact size, shape and surface area. IamFluidics’ high-yield and high-quality microencapsulation processes are a perfect match to this end. We have developed the ApiBead™ platform to tailor microbead properties for the controlled delivery of active pharmaceutical ingredients (APIs).

More about ApiBead

The advantage of monodispersity

Monodisperse or uniformly sized microparticles offer various advantages over polydisperse ones. Spherical monodisperse particles, combined with a tightly controlled particle size distribution have a significant positive effect on injectability¹, flowability² and release profiles³. With these three key attributes the delivery and performance of APIs can be enhanced.

ApiBead™ is developed to deliver just that: monodisperse, perfectly shaped spheres with a tuneable controlled particle size distribution at CV<10%:

^{1. Sarmadi et al., Science Adv., 2020, 6, eabb6594.}
^{2. Liu et al., Int. J. Pharm., 2008, 362, 109.}
^{3. Berkland et al., J. Control. Release, 2002, 82, 137.}

Source: IamFluidics

Scalable & Sustainable

With our continuous microfluidic process, we create monodisperse microparticles in the air, free of oils and surfactants.
The process uses less toxic solvents (class 3) than conventional processes.
Our perfect spheres are produced at jet speed (ml/min), chip-free and a 1000 times faster than conventional microfluidic systems.
Production is conducted under strict in-line control, tuneable for particle size, material choice and sphere morphology fit for you API.
The process is scalable for both R&D and pre-clinical purposes at g/day and clinical and commercial purposes kg/day with waste minimization and yield optimization in mind.

Our beads in your formulation

For an optimized administration, delivery format, powder flow and release profile of your API, partner with us to design your beads / capsules with the right: